NCT02739373View on ClinicalTrials.gov

Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

December 14, 2016

Study Completion Date

December 14, 2016

Conditions
Severe Sepsis
Interventions
DRUG

BMS-986189

OTHER

Placebo

Trial Locations (1)

47710

Covance Clinical Research Unit, Inc., Evansville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02739373 - Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects | Biotech Hunter | Biotech Hunter